What the trial was testing
The trial enrolled 4 patients with colorectal cancer. The study was sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
The drug shrank 16 out of 20 tracked polyps and reduced the total count in all four patients.
BMJ open gastroenterology · 2020 · NCT03095703
These findings — that shrank after six months of treatment — were published in the BMJ open gastroenterology and represent the headline result of the study.
Researchers tracked outcomes across 4 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with colorectal cancer, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This was an early-stage study in just four people, so this treatment is not yet standard care. If you have FAP and continue to develop polyps after surgery, talk to your doctor about whether sirolimus or other options might be right for you. The drug showed promise but caused side effects in everyone who took it.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open colorectal cancer trials
Prevention of Oxaliplatin-induced Nerve Damage in the Body's Extremities
The purpose of this study is to examine the effect of supplementary polyunsaturated fatty acids on nerve damage in the body's extremitites of patients treated with oxaliplatin containing chemotherapy after surgery for colorectal cancer.
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
This is a phase 1 multi-center, open-label study evaluating IBI3028 Treatment in participants with locally advanced, unresectable, or metastatic solid tumors